Introduction
For patients with acute myeloid leukemia (AML), failure to achieve complete remission after induction therapy or relapse after complete remission represents the major barrier to cure for both children and adults. Despite recent efforts to improve risk stratification and to incorporate targeted therapies into AML care, relapse rates remain approximately 30% and 50% for children and adults with AML, respectively [1] [2] [3] . Whilst leukemia cytogenetics at the time of diagnosis has proven to be the most useful prognostic biomarker of clinical outcomes and therapy stratification, patients with cytogenetically normal (CN) AML encompass the largest group for whom prognostication and therapy selection are hindered by the lack of prognostic markers and effective therapeutic targets.
Genomic profiling has been used to stratify patients with CN AML, identifying recurrent somatic gene mutations, such as those in NPM1, TET2, ASXL1, and DNMT3A, that are significantly associated with clinical outcomes 4, 5 . Recent studies using whole-genome sequencing have assessed the mutational landscape of relapsed AML in adults identifying two major patterns of clonal evolution in response to chemotherapy: 1) persistence of the dominant pre-leukemic clone with mutations acquired at relapse, and 2) expansion of a diagnostic subclone, emphasizing the importance of therapeutically targeting specific molecular mechanisms that contribute to chemotherapy resistance [6] [7] [8] . Similar observations were recently made using genomic studies of pediatric AML, with specific variant allele frequencies representing potential prognostic indicators 9 . Clonal persistence after induction chemotherapy appears to be associated with the increased risk of relapse 10 , but whether these mutant clones directly cause chemoresistance or reflect age-related clonal hematopoiesis remains to be determined 11 .
4 malignancies to identify diagnostic gene mutations that are associated with primary chemoresistance in adult and pediatric CN AML.
Study design

Patient Selection
Specimens were collected from patients treated at the Memorial Sloan Kettering Cancer
Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, Ohio State University
Comprehensive Cancer Center, and Children's Oncology Group (COG) participating institutions.
All patients provided informed consent, were enrolled on respective institutional research protocols and treated using current institutional remission induction regimens (Table 1) . Primary chemoresistance was defined based on the presence of at least 5% AML blasts by morphologic assessment of bone marrow aspirates obtained after two cycles of induction chemotherapy, as assessed by the respective institutional or central pathologic review.
Targeted Gene Sequencing
Mononuclear cells isolated from bone marrow aspirates obtained at diagnosis were purified by Ficoll gradient centrifugation, and enriched for leukemia cells by negative immunomagnetic selection against CD3, CD14, CD19 and CD235a given the lack of expression of these markers by the majority of AML cells 12 . Targeted DNA and RNA capture and sequencing of 670 genes (405 genes in DNA and 265 genes in RNA) known to be recurrently mutated in hematologic malignancies were performed using the Foundation One Heme sequencing platform. Extraction of DNA and RNA, library preparation and Illumina sequencing were carried out as previously described 13 . Sequencing data were analyzed to identify genomic alterations including base substitutions, insertions, deletions, and gene fusions 13 . Differential gene expression analysis was performed based on per million processing regions (PPM) gene expression measurements, as median normalized to all other AML specimens analyzed to peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/051177 doi: bioRxiv preprint first posted online Apr. 30, 2016; date 13 . All statistical comparisons were corrected for multiple hypothesis testing using the Bonferroni correction, and statistical significance was calculated as indicated.
Results and Discussion
We were able to obtain genomic profiles of 107 CN AML specimens in total, collected from 55 adults and 52 children, balanced for outcome groups, gender and age (Table 1) . No significant differences were observed in the total number of coding mutations between the primary failure of induction chemotherapy and complete remission outcome groups for both pediatric and adult cohorts (Supplemental Table 1 ). Consistent with previous studies, the most frequently mutated genes among adults were DNMT3A (49%), FLT3 (42%) and NPM1 (42%), and for pediatric patients FLT3 (54%), NRAS (27%), and WT1 (25%), which were not significantly associated with either outcome group ( Figure 1 ). Mutations of DNMT3A and NPM1
were relatively rare in pediatric (2%) as compared to adult cases (p < 0.001, permutation test).
In contrast, CEBPA mutations were more frequently observed in pediatric as compared to adult CN AML (21% versus 2%, respectively, p < 0.001, permutation test).
Genomic profiling also identified 15 gene rearrangements among the 21 specimens for which diagnostic material of adequate quality was available for RNA capture (Supplemental Table 1 ). Cryptic rearrangements of known genes in AML were detected, including KMT2A
(MLL) and NUP98-NSD1. The latter was observed in only pediatric patients from this study, consistent with previous reports 14, 15 . We identified several novel cryptic gene rearrangements including intergenic deletions involving NOTCH1/EDF1 and GATA2/DNAJB8, as well as translocations leading to the rearrangements of SQSTM1-NUP214 and IGH-BCL2. Mutations of these genes have been reported in hematologic malignancies, for example the SQSTM1-NUP214 gene fusion in cases of T-cell acute lymphoblastic leukemias (ALL), but not in AML 16 .
In addition, our study identified potential novel coding mutations in MAP3K1 (MEKK), MAP3K6
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We assessed whether any gene mutations were significantly associated with primary chemoresistance as compared to complete remission among the adult and pediatric patients in the studied cohorts. This identified mutations of SETBP1 (8 out In addition, using available RNA sequencing and gene expression data, we assessed whether genes included in our analysis were significantly altered in expression in the induction failure as compared to complete remission cohorts (Supplemental Table 2 ). This analysis revealed significant overexpression of genes encoding the DNA damage repair and response In summary, we have assessed the mutational landscape of cytogenetically normal AML at diagnosis in adults and children to determine the genetic basis of induction failure and primary chemoresistance. In spite of careful selection of cytogenetically normal specimens, our study identified numerous cryptic gene rearrangements, including those that have potential therapeutic implications. Likewise, we found novel gene alterations including lesions that have been observed in non-myeloid hematologic malignancies, some of which may be pathogenic. In addition, our analysis revealed significant overexpression of genes that are associated with primary chemoresistance. Though mutations of SETBP1, ASXL1 and RELN appear to be associated with primary chemoresistance and induction failure in our study, their prevalence was relatively low. We did not identify single gene mutations that are significantly associated with primary chemoresistance and induction failure in the majority of the patients studied. It is possible that additional genetic lesions such as those not included in the current target gene panel 13 , or alternatively, combinations of genetic alterations that are below the statistical power of our study may cause primary chemoresistance and failure in AML, which may be elucidated by larger and more comprehensive genomic profiling studies. Finally, it remains to be determined whether functional molecular profiling such as that achieved using gene expression, epigenetic and proteomic analyses may reveal more universal biomarkers and therapeutic targets to prospectively identify and therapeutically block chemotherapy resistance in AML [22] [23] [24] [25] .
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